01-07-2024 20:33 via medpagetoday.com

Duchenne Muscular Dystrophy Gene Therapy

(MedPage Today) -- The FDA's recent expanded approval of delandistrogene moxeparvovec (Elevidys) widened access to the gene therapy to include ambulatory and non-ambulatory Duchenne muscular dystrophy patients ages 4 and older with a confirmed...
Read more »